Article
Gastroenterology & Hepatology
Penglei Jiang, Hongyu Jia, Xinyue Qian, Tian Tang, Yingli Han, Zhaoru Zhang, Lingli Jiang, Zebin Yu, Lin Zheng, Guodong Yu, Huan Cai, Shanyan Zhang, Xiaoli Zhang, Jueqing Gu, Chanyuan Ye, Lisha Yang, Yingfeng Lu, Heng Liu, Xiaoqing Lu, Ciliang Jin, Yue Ren, Miaomiao Lu, Lingling Xu, Jiong Yu, Xi Jin, Yida Yang, Pengxu Qian
Summary: This study used single-cell RNA sequencing to investigate the transcriptomic landscape of peripheral immune cells in CHB patients before and after PegIFN-alpha therapy. The study identified specific cell subsets associated with CHB and found that PegIFN-alpha treatment could decrease hyperactivated monocytes, increase long-lived naive/memory T cells, and enhance effector T cell cytotoxicity. Furthermore, the treatment altered the transcriptional profiles of immune cells and enhanced innate antiviral response.
Article
Gastroenterology & Hepatology
Jose-Manuel Ramos-Rincon, Hector Pinargote-Celorio, Carmen de Mendoza, Clara Ramos-Belinchon, Pablo Barreiro, Ana Trevino, Octavio Corral, Vicente Soriano
Summary: The rate of hepatic decompensation events and liver cancer has declined and/or plateaued in recent years for patients hospitalized with HBV and HCV infections, following the widespread use of oral antiviral therapies for these viruses. In contrast, the rate of decompensated cirrhotic events and HCC has kept rising up for patients with hepatitis delta, for which effective antiviral treatment does not exist yet.
HEPATOLOGY INTERNATIONAL
(2022)
Article
Gastroenterology & Hepatology
Ethan M. Weinberg, Michael P. Curry, Catherine T. Frenette, Fredric G. Regenstein, Eugene R. Schiff, Zachary D. Goodman, James M. Robinson, Jean L. Chan, Joanne C. Imperial, K. Rajender Reddy
Summary: The study found that Emricasan can reduce or prevent the progression of hepatic fibrosis in HCV liver transplant recipients, especially showing significant improvement in fibrosis stability and improvement in the F3 to F5 subgroup.
LIVER TRANSPLANTATION
(2021)
Article
Gastroenterology & Hepatology
Byungyoon Yun, Sang Hoon Ahn, Jin-Ha Yoon, Beom Kyung Kim
Summary: This study found a significant association between long-term aspirin use and reduced HCC risk in patients with chronic HBV, and observed significant correlation in certain clinical conditions.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Immunology
Xiaoan Yang, Ka Zhang, Qihuan Xu, Xin Shu, Zhishuo Mo, Dongying Xie, Zhiliang Gao, Hong Deng
Summary: This study aimed to investigate whether interferon-experienced patients could achieve the same HBsAg clearance and seroconversion rates as interferon-naive patients, and to clarify the associated factors and cut-offs. The results showed satisfactory clinical cure of interferon add-on therapy for interferon-experienced patients with low HBsAg. Age, baseline HBsAg, and week 12 HBsAg were negatively correlated with week 48 HBsAg clearance and seroconversion. Interferon-experienced patients with low HBsAg were suggested with interferon add-on therapy for achieving clinical cure.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Michal Brzdek, Krystyna Dobrowolska, Pawel Pabjan, Dorota Zarebska-Michaluk
Summary: The study analyzed changes in patient profile and antiviral treatment characteristics over time in a sample of 963 consecutive HCV-infected patients who received IFN-free treatment in Poland. The findings showed a decrease in patient age, comorbidities, and liver cirrhosis, as well as an increase in treatment-naive individuals and the use of pangenotypic regimens.
POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ
(2022)
Article
Oncology
Fangjie Liu, Bo Qiu, Yu Xi, Yifeng Luo, Qiaoting Luo, Yingjia Wu, Naibin Chen, Rui Zhou, Jinyu Guo, Qingping Wu, Mai Xiong, Hui Liu
Summary: This study evaluated the efficacy of thymosin alpha 1 in managing radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. The results showed significant reductions in Grade >= 2 radiation pneumonitis and Grade 3 to 4 lymphopenia in patients who received thymosin alpha 1 treatment.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Review
Gastroenterology & Hepatology
Tiffany Khoo, Danielle Lam, John K. Olynyk
Summary: Modern antiviral therapy for chronic hepatitis B and C has had positive impacts on clinical outcomes, including reducing prevalence and transmission rates, improving quality of life, lowering rates of liver decompensation and mortality, preventing progression to cirrhosis, reducing the risk of hepatocellular carcinoma, and decreasing the need for liver transplantation.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Jeong Heo, Ja-Der Liang, Chang Won Kim, Hyun Young Woo, I-Lun Shih, Tung-Hung Su, Zhong-Zhe Lin, So Young Yoo, Stanley Chang, Yasuo Urata, Pei-Jer Chen
Summary: OBP-301 is a modified oncolytic adenovirus that can replicate within cancer cells and cause their lysis. This phase I trial aimed to determine the safety and optimal dosage of OBP-301 in patients with advanced hepatocellular carcinoma. The study found that OBP-301 was well tolerated, with a maximum tolerated dose of 6 x 1012 viral particles. Injection of OBP-301 resulted in increased levels of CD8+ T cells and showed potential antitumor efficacy.
Article
Gastroenterology & Hepatology
Gulce Sari, Claudia E. Mulders, Jingting Zhu, Gertine W. van Oord, Zongdi Feng, Jolanda J. C. Kreeft-Voermans, Andre Boonstra, Thomas Vanwolleghem
Summary: PegIFN lambda is well tolerated in mice and leads to clearance of a persistent HEV infection in liver-humanized mice. The study found that human liver cells express the IFN lambda receptor and are responsive to pegIFN lambda. Dose escalation studies showed that a dose of 0.3 mg/kg pegIFN lambda treatment resulted in complete clearance of HEV antigen and HEV RNA from the liver in 8 out of 9 liver-humanized mice, demonstrating the potential efficacy of pegIFN lambda in treating chronic HEV infections.
LIVER INTERNATIONAL
(2021)
Article
Virology
Matteo Nazzareno Barbaglia, James Michael Harris, Artem Smirnov, Michela Emma Burlone, Cristina Rigamonti, Mario Pirisi, Rosalba Minisini, Andrea Magri
Summary: 17β-estradiol induces an interferon-mediated antiviral state in hepatocytes, pre-activating immune response signaling to control and suppress viral spread.
Review
Biochemistry & Molecular Biology
Phumelele Yvonne Siphepho, Yi-Ting Liu, Ciniso Sylvester Shabangu, Jee-Fu Huang, Chung-Feng Huang, Ming-Lun Yeh, Ming-Lung Yu, Shu-Chi Wang
Summary: Metabolic derangement, particularly steatosis, is common in HCV-infected patients and may independently affect treatment outcomes. Genotype 3 HCV-infected patients have higher prevalence and severity of steatosis compared to other genotypes.
Article
Medicine, General & Internal
Pei-Yuan Su, Yang-Yuan Chen, Jun-Hung Lai, Hung-Ming Chen, Chih-Ta Yao, I-Ling Liu, Ya-Huei Zeng, Siou-Ping Huang, Yu-Chun Hsu, Shun-Sheng Wu, Fu-Yuan Siao, Hsu-Heng Yen
Summary: This study evaluated the safety and efficacy of glecaprevir/pibrentasvir in patients with compensated cirrhosis in a real-world setting. The treatment regimen was found to be highly effective and well tolerated among these patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Anika Wranke, Benjamin Heidrich, Katja Deterding, Katharina Luise Hupa-Breier, Janina Kirschner, Birgit Bremer, Markus Cornberg, Heiner Wedemeyer
Summary: The study found that patients with HDV infection had earlier and more frequent clinical complications compared to HBV. However, in cirrhotic patients, there were no significant differences between HBV and HDV in the development of liver-related end points, but CHB patients with cirrhosis were more likely to develop HCC than CHD patients with cirrhosis.
HEPATOLOGY INTERNATIONAL
(2023)
Article
Gastroenterology & Hepatology
Katja Dinkelborg, Julia Kahlhoefer, Petra Doerge, Cihan Yurdaydin, Svenja Hardtke, Florin Alexandru Caruntu, Manuela G. Curescu, Kendal Yalcin, Ulus S. Akarca, Selim Gurel, Stefan Zeuzem, Andreas Erhardt, Stefan Lueth, George Papatheodoridis, Onur Keskin, Kerstin Port, Monica Radu, Mustafa K. Celen, Ramazan Idilman, Kristina Weber, Judith Stift, Ulrike Wittkop, Benjamin Heidrich, Ingmar Mederacke, Heiko von der Leyen, Hans Peter Dienes, Markus Cornberg, Armin Koch, Michael P. Manns, Heiner Wedemeyer, Katja Deterding
Summary: This study investigated the impact of antiviral therapy with pegylated interferon alfa on the quality of life of hepatitis D virus (HDV) infected patients. The results showed that HDV patients had lower quality of life compared to the reference population, but pegylated interferon alfa treatment had minimal impact on quality of life. Improvement of fibrosis during treatment was associated with increased quality of life.
LIVER INTERNATIONAL
(2023)
Article
Gastroenterology & Hepatology
Richard K. Sterling, Wendy C. King, Mandana Khalili, David E. Kleiner, Amanda S. Hinerman, Mark Sulkowski, Raymond T. Chung, Mamta K. Jain, Mauricio Lisker-Melman, David K. Wong, Marc G. Ghany
Summary: This study evaluated the diagnostic performance of four noninvasive serum-based scores for detecting hepatic steatosis in chronic HBV cohorts, showing moderate diagnostic efficacy. The relative utility of these scores differed by co-infection/anti-HBV medication status, with population-specific cutoffs providing only moderate utility.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Raymond T. Chung, Wendy C. King, Marc G. Ghany, Mauricio Lisker-Melman, Amanda S. Hinerman, Mandana Khalili, Mark Sulkowski, Mamta K. Jain, Eun-Young K. Choi, Michael A. Nalesnik, Atul K. Bhan, Gavin Cloherty, David K. Wong, Richard K. Sterling
Summary: This study evaluated the role of HBV RNA and HBcrAg in characterizing HBV-HIV coinfection and found that the use of novel HBV markers can continue to improve the suppression of HBV transcription and translation in suppressive dually active antiviral therapy. However, for HBeAg patients, the benefit of combination antiviral therapy is limited.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Infectious Diseases
Andinet Gizaw, Wendy C. King, Amanda S. Hinerman, Raymond T. Chung, Mauricio Lisker-Melman, Marc G. Ghany, Mandana Khalili, Mamta K. Jain, Jacob Graham, Theresa Swift-Scanlan, David E. Kleiner, Mark Sulkowski, David K. Wong, Richard K. Sterling
Summary: This study suggests that TDF use in HBV-HIV co-infected adults can lead to worsening renal function and bone turnover.
Article
Gastroenterology & Hepatology
Mauricio Lisker-Melman, Abdus S. Wahed, Marc G. Ghany, Raymond T. Chung, Wendy C. King, David E. Kleiner, Atul K. Bhan, Mandana Khalili, Mamta K. Jain, Mark Sulkowski, David K. Wong, Gavin Cloherty, Richard K. Sterling
Summary: In patients coinfected with HBV and HIV, HBV RNA and HBcrAg can still be detected despite viral suppression, and their levels are associated with the extent of HBsAg and HBcAg staining in liver cells. This suggests that residual transcription and translation may contribute to liver pathology even when viral replication is suppressed.
Review
Gastroenterology & Hepatology
David Yardeni, Kyong-Mi Chang, Marc G. Ghany
Summary: Hepatitis B virus is a major cause of cirrhosis and hepatocellular carcinoma, and despite the availability of an effective vaccine, chronic infection continues to be prevalent. Current therapies are effective at suppressing the virus during treatment, but do not provide long-term viral suppression. There is a need for novel therapies that can achieve functional or complete cure by targeting key components of the virus. This review discusses current best practices for managing chronic HBV infection and new emerging therapies with the potential for a cure.
Article
Gastroenterology & Hepatology
Nehna Abdul Majeed, Ahmad Samer Alawad, Kin Seng Liem, Varun Takyar, Harvey Alter, Jordan J. Feld, Harry L. A. Janssen, Marc G. Ghany
Summary: This study evaluated the rate of hepatitis B virus (HBV) reactivation in patients with chronic hepatitis C (CHC) during direct acting antiviral (DAA) therapy. The risk of HBV reactivation was found to be low, and testing for HBV DNA is recommended only in patients with ALT flares or failure of ALT normalization during DAA treatment.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Herbert L. Bonkovsky, Sean P. Rudnick, Christopher D. D. Ma, Jessica R. Overbey, Kelly Wang, Denise Faust, Csilla Hallberg, Karli Hedstrom, Hetanshi Naik, Akshata Moghe, Karl E. Anderson
Summary: Ledipasvir/sofosbuvir is effective for treating both chronic hepatitis C (CHC) and porphyria cutanea tarda (PCT) without the need for additional treatment methods.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Marc G. Ghany, Wendy C. King, Amanda S. Hinerman, Anna SF. Lok, Mauricio Lisker-Melman, Raymond T. Chung, Norah Terrault, Harry L. A. Janssen, Mandana Khalili, William M. Lee, Daryl T. Y. Lau, Gavin A. Cloherty, Richard K. Sterling
Summary: This study examined the predictive ability of HBV RNA and HBcrAg for patients with chronic hepatitis B (CHB) and found that they could predict key events such as not sustained inactive carrier phase, ALT flare, HBeAg loss, and HBsAg loss. However, their addition to readily available markers provided only small improvements in predictive ability.
Article
Gastroenterology & Hepatology
Marc G. Ghany, Maria Buti, Pietro Lampertico, Hannah M. Lee
Summary: Representatives from academia, industry, regulatory agencies, and patient advocacy groups convened under the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) in June 2022 to achieve consensus on chronic HBV and HDV treatment endpoints. The conference focused on the primary goal of guiding clinical trials aiming to cure HBV and HDV, and reached agreements on key points such as preferred endpoints for trials, suitable patient candidates, and the role of novel biomarkers and existing therapies.
Article
Gastroenterology & Hepatology
David J. Kuter, Herbert L. Bonkovsky, Susana Monroy, Gayle Ross, Encarna Guillen-Navarro, Maria Domenica Cappellini, Anna-Elisabeth Minder, Ole Hother-Nielsen, Paolo Ventura, Gang Jia, Marianne T. Sweetser, Manish Thapar
Summary: Long-term monthly givosiran treatment provides sustained improvement in clinical manifestations of acute hepatic porphyria (AHP) with a positive risk/benefit profile.
JOURNAL OF HEPATOLOGY
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Donald Wunsch, Elizabeth C. Wright, Sungyoung Auh, Joni Trenbeath, Marc G. Ghany
Meeting Abstract
Gastroenterology & Hepatology
Zahra Sarrafan-Chaharsoughi, Varun Takyar, Sungyoung Auh, Ahmad Alawad, Brent S. Abel, Devika Kapuria, Colleen Byrnes, Anna Wolska, David E. Kleiner, Robert D. Shamburek, Alan T. Remaley, Marc G. Ghany
Meeting Abstract
Gastroenterology & Hepatology
Daryl Lau, Elena Kim, Chosha Bai, Wendy King, Yixiao Cui, David E. Kleiner, Marc G. Ghany, Thi Thuy Tu Nguyen, Amanda Hinerman, Zhili Wang, Raymond T. Chung, Richard K. Sterling, Gavin A. Cloherty, Ying-Hsiu Su, Haitao Guo
Meeting Abstract
Gastroenterology & Hepatology
Mohamed Hassan, Kelsey R. Leonard, Marc G. Ghany, Mandana Khalili, Lewis R. Roberts, Richard K. Sterling, Steven H. Belle, Anna Lok
Meeting Abstract
Gastroenterology & Hepatology
Daryl Lau, Elena Kim, Chosha Bai, Wendy C. King, Yixiao Cui, David E. Kleiner, Marc Ghany, Thi Thuy Tu Nguyen, Amanda S. Hinerman, Zhili Wang, Raymond Chung, Richard Sterling, Gavin Cloherty, Ying-Hsiu Su, Haitao Guo
JOURNAL OF HEPATOLOGY
(2022)